Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Neuprex recombinant bactericidal/permeability-increasing protein regulatory update

WIR Staff
May 1, 2000 7:00 AM UTC

XOMA said the FDA determined that data from XOMA's Phase III trial of Neuprex to treat meningococcemia were not sufficient to support the filing of a BLA. The data, reported by XOMA and partner BAX fr...